Condition: Venous Thromboembolism (VTE) · Postpartum · Sponsor: Marc Blondon
The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.
This description comes directly from the study's public registry record.
Marc Blondon · (+41).22.372.92.92 · marc.blondon@hug.ch
Always discuss trial participation with your own doctor first.
| Kantonsspital Baden | Baden, Switzerland | Recruiting |
| Universitätsspital Basel | Basel, Switzerland | Recruiting |
| Lindenhofspital | Bern, Switzerland | Recruiting |
| Geneva University Hospitals | Geneva, Switzerland | Recruiting |
| Centre Hospitalier Universitaire Vaudois | Lausanne, Switzerland | Recruiting |
| Ente Ospedaliero Cantonale | Lugano, Switzerland | Recruiting |
| Réseau Hospitalier Neuchâtelois | Neuchâtel, Switzerland | Recruiting |
| Hôpital du Valais | Sion, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07140211